Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F6SY
|
|||
| Former ID |
DIB014037
|
|||
| Drug Name |
StarGen
|
|||
| Synonyms |
Juvenile degenerative retinal disease therapy, Oxford BioMedica; ABCR gene therapy (Stargardt disease, LentiVector), Oxford BioMedica
Click to Show/Hide
|
|||
| Indication | Retinitis pigmentosa [ICD-11: 9B70; ICD-10: H35.5] | Phase 1/2 | [1] | |
| Company |
Oxford BioMedica plc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ATP-binding cassette transporter A4 (ABCA4) | Target Info | Modulator | [2] |
| KEGG Pathway | ABC transporters | |||
| Reactome | Retinoid cycle disease events | |||
| The canonical retinoid cycle in rods (twilight vision) | ||||
| ABC-family proteins mediated transport | ||||
| WikiPathways | Visual phototransduction | |||
| ABC-family proteins mediated transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01736592) A Study to Determine the Long Term Safety, Tolerability and Biological Activity of StarGen in Patients With Stargardt's Macular Degeneration. U.S. National Institutesof Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Oxford BioMedica. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.